Yes, actin binding can be therapeutically targeted. Small molecules and peptides that modulate actin polymerization and ABP interactions are being developed. For example, cytochalasins inhibit actin polymerization and are used in research to study actin dynamics. Additionally, researchers are exploring the use of actin-binding drugs to prevent metastasis in cancer by inhibiting cell motility.